Betmiga貝坦利

Betmiga Dosage/Direction for Use

mirabegron

Manufacturer:

Astellas

Distributor:

Firma Chun Cheong
/
DKSH
Full Prescribing Info
Dosage/Direction for Use
Posology: Adults (including elderly patients): The recommended dose is 50 mg once daily with or without food.
Special populations: Renal and hepatic impairment: Betmiga has not been studied in patients with end stage renal disease (GFR < 15 mL/min/1.73 m2 or patients requiring haemodialysis) or severe hepatic impairment (Child-Pugh Class C) and it is therefore not recommended for use in these patient populations (see Precautions and Pharmacology: Pharmacokinetics under Actions).
The following table provides the daily dosing recommendations for subjects with renal or hepatic impairment in the absence and presence of strong CYP3A inhibitors (see Precautions, Interactions and Pharmacology: Pharmacokinetics under Actions). (See Table 4.)

Click on icon to see table/diagram/image

Gender: No dose adjustment is necessary according to gender.
Paediatric population: The safety and efficacy of mirabegron in children below 18 years of age have not yet been established.
No data are available.
Method of administration: The tablet is to be taken once daily, with liquids, swallowed whole and is not to be chewed, divided, or crushed.
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in